XML 56 R39.htm IDEA: XBRL DOCUMENT v3.22.0.1
Segment Information (Tables)
 6 Months Ended
Dec. 31, 2021
Segment Reporting [Abstract]  
Net Revenue by Segment
(Dollars in millions)Three Months Ended  
December 31,		Six Months Ended  
December 31,
2021202020212020
Net revenue:
Biologics$638 $404 $1,184 $781 
Softgel and Oral Technologies329 247 572 468 
Oral and Specialty Delivery156 170 302 328 
Clinical Supply Services99 93 195 186 
Inter-segment revenue elimination(5)(3)(11)(6)
Total net revenue$1,217 $911 $2,242 $1,757 
Reconciliation of Earnings/(Loss) from Continuing Operations to EBITDA
(Dollars in millions)Three Months Ended  
December 31,		Six Months Ended  
December 31,
2021202020212020
Segment EBITDA reconciled to net earnings:
Biologics$197 $136 $363 $242 
Softgel and Oral Technologies78 46 119 83 
Oral and Specialty Delivery44 44 77 66 
Clinical Supply Services27 25 53 50 
Sub-Total$346 $251 $612 $441 
Reconciling items to net earnings
Unallocated costs (1)
(101)(45)(157)(74)
Depreciation and amortization(98)(71)(179)(140)
Interest expense, net(32)(26)(58)(51)
Income tax expense(18)(21)(28)(5)
Net earnings$97 $88 $190 $171 
(1) Unallocated costs include restructuring and special items, stock-based compensation, gain on sale of subsidiary, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows:                                                            
(Dollars in millions)Three Months Ended  
December 31,
Six Months Ended  
December 31,
2021202020212020
Impairment charges and gain (loss) on sale of assets (a)
$(16)$(1)$(19)$(2)
Stock-based compensation(11)(11)(32)(30)
Restructuring and other special items (b)
(23)(15)(31)(20)
Gain on sale of subsidiary (c)
— — 1 — 
Other (expense) income, net (d)
(14)8 (23)19 
Unallocated corporate costs, net(37)(26)(53)(41)
Total unallocated costs$(101)$(45)$(157)$(74)

(a)    Impairment charges and gain (loss) on sale of assets during the three and six months ended December 31, 2021 include fixed asset impairment charges associated with a product in our respiratory and specialty platform.
(b)    Restructuring and other special items during the three months ended December 31, 2021 include (i) transaction and integration costs primarily associated with the Bettera acquisition and (ii) restructuring costs associated with the closure of the Bolton facility. Restructuring and other special items during the six months ended December 31, 2021 include (i) transaction and integration costs associated with the Delphi, Hepatic, RheinCell, and Bettera acquisitions and (ii) restructuring costs associated with the closure of the Bolton facility.
Restructuring and other special items during the three and six months ended December 31, 2020 include (i) transaction costs associated with the sale of the Blow-Fill-Seal Business and (ii) restructuring costs associated with the closure of the Bolton facility. Restructuring and other special items during the six months ended December 31, 2020 also include transaction and integration costs associated with acquisitions of facilities in Italy and Belgium, the disposal of a site in Australia, and other restructuring initiatives across the Company's network of sites.
(c)    Gain on sale of subsidiary for the six months ended December 31, 2021 was due to the sale of the Blow-Fill-Seal Business.
(d)    Refer to Note 8, Other Expense (Income), Net for details of financing charges and foreign currency translation adjustments recorded within other expense (income), net.
Total Assets for Each Segment and Reconciling in Consolidated Financial Statements
The following table includes total assets for each segment, as well as reconciling items necessary to total the amounts reported in the consolidated financial statements.
(Dollars in millions)December 31,
2021		June 30,
2021
Assets:
Biologics$5,208 $4,973 
Softgel and Oral Technologies2,591 1,604 
Oral and Specialty Delivery1,210 1,269 
Clinical Supply Services465 483 
Corporate and eliminations729 783 
Total assets$10,203 $9,112